Repeat Ablation of Persistent Atrial Fibrillation, including Mitral Isthmus and Cavo-Tricuspid Isthmus Ablations, with the FARAPULSE Pulsed Field Ablation System (NCT06735534)
ReMATCH
The FARAPULSE Pulsed Field Ablation System used in this study is comprised of two medical devices called the FARAWAVE and FARAPOINT. FARAWAVE and FARAPONT are both different types of catheters that use pulsed electrical energy to treat abnormal heart rhythms. The study is looking at how safe and effective these two medical devices are when used to treat a heart condition called persistent atrial fibrillation (PersAF) after a failed initial ablation procedure.
Program & service
This trial is being run with the Heart & Lung service, and as part of the Cardiology program.
Trial phase
Other
Trial participation type
This trial has been designed for the Clinical Research of a Device.
Principal investigator
Prof Peter Kistler
Key inclusion data
Single previous AF Ablation Procedure within 5 years prior to enrolment. Persistent AF Diagnosis. AF recurrence at least 60 days after the participant's Index Procedure. Left atrial diameter 5.5cm or LA volume <100ml. Willing to receive a subcutaneous, chronically inserted LUX-DX Implantable Cardiac Monitor device.
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTRIf you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.